Adverse effect: any adverse effects · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes adverse effect: any adverse effects compared with other treatments (very low certainty).
1 finding from 1 review
Adverse effect: any adverse effects · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: Any adverse events · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes adverse effects: Any adverse events compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects ‐ any · patients with schizophrenia
1 finding from 1 review
Adverse effects ‐ any adverse effect · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes adverse effects ‐ any adverse effect compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
POLYPEPTIDE ‐ CERULETIDE showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · patients with antipsychotic‐induced tardive dyskinesia
ANTIEPILEPTIC ‐ LEVETIRACETAM showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
Intervention not reported
Adverse effects ‐ any important adverse effects · people with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any serious, specific ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ any serious, specific adverse effects · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Adverse effects: any serious, specific ‐ dystonia during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: any serious, specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
CHLORPROMAZINE may leads to higher adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with QUETIAPINE (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Adverse effects: 1. Serious (any time point) ‐ any serious adverse effect Various methods · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in adverse effects: 1. Serious (any time point) ‐ any serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS · patients with schizophrenia
RISPERIDONE may leads to higher adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term… compared with PLACEBO (low certainty).
1 finding from 1 review